Streetbeat News

Revenues

COLB

Seven analysts have recently provided their opinions on Columbia Banking System (NASDAQ:COLB), with sentiments ranging from bullish to bearish. Over the past three months, there have been 2 somewhat bullish and 5 indifferent ratings, with no bullish or bearish ratings. The 12-month price targets show an average of $25.14, down from the previous $31.50. Analysts from firms like RBC Capital, DA Davidson, and others have adjusted their ratings and price targets, generally lowering them. Columbia Banking System is a bank holding company with a subsidiary, Columbia State Bank, offering a range of banking services. The company has shown a revenue growth of 65.54% as of September 30, 2023, a net margin of 25.88%, an ROE of 2.87%, and an ROA of 0.26%, but has a high debt-to-equity ratio of 0.98.

Portfolio Pulse from Benzinga Insights

January 25, 2024 | 6:01 pm

INTU

Financial analysts have provided varying ratings for Intuit (NASDAQ:INTU) over the last quarter, with an average 12-month price target of $623.58, reflecting an 11.35% increase from the previous target. Recent actions by analysts mostly involve raising price targets and maintaining positive ratings. Intuit's financial performance shows a 14.67% revenue growth rate but below-average net margin, ROE, and ROA. The company has a lower debt-to-equity ratio compared to industry norms.

Portfolio Pulse from Benzinga Insights

January 25, 2024 | 6:01 pm

RMD

Analysts have updated their ratings and price targets for ResMed (NYSE:RMD) over the past three months, with a mix of bullish and indifferent stances. The average 12-month price target is now $188.0, up from $175.25, with a high estimate of $215.00 and a low of $160.00. ResMed's financial performance is strong, with a revenue growth rate of 16.0%, a net margin of 19.91%, an ROE of 5.24%, an ROA of 3.25%, and a low debt-to-equity ratio of 0.35. The company is well-positioned in the respiratory care device market, with a focus on digital health and a growing market due to increasing diagnoses of sleep apnea.

Portfolio Pulse from Benzinga Insights

January 25, 2024 | 6:00 pm

CTAS

Seven financial analysts have recently updated their ratings on Cintas (NASDAQ:CTAS), with a mix of bullish and indifferent stances. The average 12-month price target for CTAS has increased to $627.14, up from $568.67, with individual targets ranging from $585.00 to $660.00. Analysts from firms including Truist Securities, Stifel, JP Morgan, RBC Capital, and Deutsche Bank have raised their price targets, reflecting a positive outlook on the company's performance. Cintas, known for its uniform rental programs and facility services, has shown a revenue growth rate of 9.3%, a net margin of 15.7%, an ROE of 9.25%, and an ROA of 4.26%, with a debt-to-equity ratio of 0.72.

Portfolio Pulse from Benzinga Insights

January 25, 2024 | 6:00 pm

EDU

Shares of New Oriental (EDU) are up following the company's report of Q2 sales that exceeded expectations. Additionally, the company provided guidance for Q3.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 5:15 pm

BOKF

In the last three months, 4 analysts have provided ratings on BOK Financial (NASDAQ:BOKF), all maintaining an 'Indifferent' stance. The average 12-month price target is $90.75, with a high of $98.00 and a low of $78.00. The current average target has decreased by 1.71% from the previous $92.33. BOK Financial's financial performance shows a -1.28% decline in revenue growth, a high net margin of 27.27%, an ROE of 2.76%, and an ROA of 0.27%, but a concerning debt-to-equity ratio of 1.31.

Portfolio Pulse from Benzinga Insights

January 25, 2024 | 5:01 pm

ELV

Elevance Health (NYSE:ELV) has received mixed analyst ratings over the past three months, with 4 somewhat bullish ratings. The average 12-month price target is $555.00, with a high of $574.00 and a low of $547.00, reflecting a 2.72% decrease from the previous average. Analysts from RBC Capital, Cantor Fitzgerald, and JP Morgan have provided updates, with actions ranging from maintaining to raising and lowering ratings and price targets. Elevance Health is a major health insurer in the U.S. with significant market capitalization, revenue growth, and financial performance indicators such as net margin, ROE, and ROA, but carries a higher debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 25, 2024 | 5:01 pm

SLM

SLM Corp (NASDAQ:SLM) has been analyzed by 9 analysts, showing diverse opinions with an average 12-month price target of $20.28, up 16.55% from the previous $17.40. Recent actions by analysts include raised price targets and ratings, indicating a positive outlook. Despite this, SLM faces financial challenges with a -12.0% revenue decline, below-average net margin, ROE, and ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 25, 2024 | 5:01 pm

RYTM

Rhythm Pharmaceuticals (NASDAQ:RYTM) has received 7 analyst ratings in the past quarter, with a consensus 12-month price target of $48.14, up from $38.86. Analysts from Goldman Sachs, Needham, Morgan Stanley, and Wells Fargo have raised their price targets, reflecting a bullish sentiment. The company's financials show a significant revenue growth rate of 425.3% and a high net margin of -196.25%, but a lower ROA of -13.3%. RYTM is engaged in developing therapies for rare diseases and obesity caused by MC4 pathway deficiencies.

Portfolio Pulse from Benzinga Insights

January 25, 2024 | 5:00 pm

PB

Prosperity Bancshares (NYSE:PB) has been reviewed by 5 analysts over the past three months, with a mix of opinions. Recent ratings show 4 bullish and 1 indifferent stance, with no bearish views. The average 12-month price target is $72.8, a 14.34% increase from the previous $63.67. Analysts from RBC Capital, Raymond James, Truist Securities, UBS, and Citigroup have provided updates, with most raising their price targets. Prosperity Bancshares operates a community bank model in Texas and has seen a -6.47% decline in revenue growth as of September 30, 2023. Despite this, the company has a high net margin of 41.97% but a lower ROE of 1.6% and an above-average debt-to-equity ratio of 0.6.

Portfolio Pulse from Benzinga Insights

January 25, 2024 | 5:00 pm